Klinická farmakologie a farmacie – 2/2018

www.klinickafarmakologie.cz  / Klin Farmakol Farm 2019; 33(2): 36–43 / KLINICKÁ FARMAKOLOGIE A FARMACIE 43 PŘEHLEDOVÉ ČLÁNKY Lékové interakce často předepisovaných antidepresiv LITERATURA 1. Suchopár J, Prokeš M, Suchopár O. Spotřeba antidepresiv v České republice ve srovnání s ostatními vyspělými země‑ mi. Remedia 2016; 26(6): 560–566. 2. Raboch J, Červený R. Deprese, novelizace 2018. Cent‑ rum doporučených postupů pro praktické lékaře, dostup‑ né z: www.svl.cz 3. Slanař O, Drazd'áková M, Babiárová K, Pechandová K, Buzko‑ vá H, Perlík F, Zima T. Genotyping of CYP2D6 and CYP2C19. Cas Lek Cesk 2007; 146: 708–711. 4. Ústav lékařské biochemie a laboratorní diagnostiky VFN, dostupné z: https://ulbld.lf1.cuni.cz/seznam-lab-vysetre‑ ni?vysetreni=1374 5. SÚKL: Farmakoterapeutické informace 2015, 1: dostupné z: http://www.sukl.cz/sukl/2015 6. Prokeš M, Suchopár J. Serotoninový syndrom: co bychom o něm měli vědět. Med. praxi 2014; 11(5): 226–230. 7. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Phys‑ ician 2015; 18: 395–400. 8. Maniscalco I, Toffol E, Giupponi G, Conca A. The interac‑ tion of Rhodiola rosea and antidepressants. A case report. Neuropsychiatr 2015; 29: 36–38. 9. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotoner‑ gic drug interactions: A retrospective survey. Clin Infect Dis 2006; 43: 180–187. 10. Attar-Herzberg D, Apel A, Gang N, et al. The seroto‑ nin syndrome: Initial misdiagnosis. Isr Med Assoc J 2009; 11: 367–370. 11. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter sero‑ tonin toxicity criteria: simple and accurate diagnostic deci‑ sion rules for serotonin toxicity. Q J Med 2003; 96: 635–642. 12. Prokeš M, Suchopár J. Prodloužení intervalu QT způsobe‑ né léky. Med. praxi 2014; 11(1): 34–39. 13. Digby G, MacHaalany J, Malik P, et al. Multifactorial QT in‑ terval prolongation. Cardiology Journal 2010; 17: 184–188. 14. Woosley RL, Heise CW, Romero KA (www.CredibleMeds. org), QTdrugs List, [1. 3. 2018], AZCERT, Inc., 1822 Innovati‑ on Park Dr., Oro Valley, AZ 85755, USA, https://www.credi‑ blemeds.org/ 15. Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSADs and SSRI: a case-control study in the general popula‑ tion. Eur J Clin Pharmacol 2007; 63: 403–408. 16. de Abajo FJ, Garcia-Rodriques LA. Risk of upper gastro‑ intestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxin therapy. Arch Gen Psychi‑ atry 2008; 65; 65(7): 795–803. 17. Gray SL, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern med 2015; 175(3): 401–407. 18. Topinková E. Nežádoucí účinky antimuskarinik na cent‑ rální nervový systém. Urol List 2012; 10: 69–74. 19. Sheikh-Taha M, Dimassi H. Potentially inappropriate home medications among older patients with cardiovascular disea‑ se admitted to a cardiology service in USA. BMC Cardiovas‑ cular Disorders 2017; 17: 198. 20. Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf 2017; 16(1): 77–87. 21. Wang D, Lai J, Lu S, Huang M, et al. Rapid-onset hypona‑ tremia and delirium following duloxetine treatment for po‑ stherpetic neuralgia: Case report and literature review. Me‑ dicine (Baltimore). 2018 Nov; 97(46): e13178. 22. Yoon HJ, Lee KY, Sun IO. Clinical severity of drug-indu‑ ced hyponatremia: thiazides vs. psychotropics. Clin Nephrol. 2016 Jun; 85(6): 321–325. 23. Databáze lékových interakcí DrugAgency, 2019, Elek‑ tronická publikace. Dostupné z: http://lekoveinterakce.cz 24. Raboch J, Uhlíková P, Hellerová P, et al. Psychiatrie: Dopo‑ ručené postupy psychiatrické péče IV. 2014. [cit. 2019–01–16]. Dostupné z: https://psychiatrie.cz/images/stories/deni_v_ oboru/doporucene-postupy-4–2014.pdf 25. Karki SD, Masood GR. Combination risperidone and SSRI‑ -induced serotonin syndrome. Ann Pharmacother 2003; 37(3): 388–391. 26. Saito M,Yasui-Furukori N, Nakagami T, et al. Dose-depen‑ tent interaction of paroxetine with risperidone in schizophre‑ nic patients. J Clin Pharmacol 2005; 25(6): 527–532. 27. Stout SM, Nielsen J, Welage LS, et al. The influence of metoprolol dosage release formulation on the pharmacoki‑ netic drug interactions with paroxetine. J Clin Pharmacol 2011; 51: 389–396. 28. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxeti‑ ne, a cytochrome P450 2D6 inhibitor, diminishes the setere‑ oselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005; 77(4): 312–323. 29. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndro‑ me following the administration of tramadol with paroxeti‑ ne. Int J Geriatr Psychiatry 1998; 13: 343–345. 30. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychophar‑ macology 2001; 155(2): 219–220. 31. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Mo‑ nit. 2001 Aug; 23(4): 410–413. 32. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991; 6(6): 460–462.